FDA approves Adaptimmune therapy, halts vTv diabetes program; Sanofi sues Sarepta over Duchenne patents [The good, the bad, the ugly]

Off Script: A Pharma Manufacturing Podcast

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week:

The good — FDA approves Adaptimmune engineered cell therapy
The bad — FDA puts clinical hold on vTv Therapeutics diabetes program
The ugly — Sanofi sues Sarepta over manufacturing patents for Duchenne gene therapy